Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25122924 | 0.88 | DDB1 (0.48) | DDB1CRBNALDH1A1 | |
| SCHEMBL27166534 | 0.85 | CRBN (0.41) | DDB1CRBN | |
| SCHEMBL25123219 | 0.85 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL29990767 | 0.85 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL28649449 | 0.84 | DDB1 (0.53) | DDB1CRBNKDM4EALDH1A1 | |
| SCHEMBL27166407 | 0.82 | CRBN (0.39) | DDB1CRBN | |
| SCHEMBL25123324 | 0.82 | DDB1 (0.43) | DDB1CRBN | |
| SCHEMBL29991108 | 0.82 | DDB1 (0.43) | DDB1CRBN | |
| SCHEMBL29347124 | 0.80 | DDB1 (0.47) | DDB1CRBNKDM4EALDH1A1 | |
| SCHEMBL29347429 | 0.79 | DDB1 (0.48) | DDB1CRBNKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DDB1 206/4885CRBN 302/4885KDM4E 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.